Oncothal 100mg (Thalidomide)
Thalidomide is generic form of brand name Oncothal.
Oncothal is classified as immunosuppressive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes and modulates another cytokine action.
Oncothal is a prescription drug which is used under supervision of medical oncologist.
Oncothal 100mg is indicated for the treatmentin combination with dexamethasone of patients with newly diagnosed multiple myelomaand been investigation for indication in various cancer condition like renal cell carcinoma, glioblastoma multiforme and Waldenström’s macroglobulinemia
Oncothal is also indicated for the treatment of skin lesions along with leprosy
Mechanism of action
Thalidomide mechanism of action carried out in various way; it can
- Help the immune system physical assault and demolish cancer cells
- Kill or blocks the growth of cancer cells
- Affect the chemical messages that cancer cells need to survive
- Stop the production of new blood vessels which cancer cells require to grow and spread.
Absorption: Duration to high plasma concentration is 2.9 to 5.7 hours
Distribution: plasma protein binding is 55% and 66% for the (+) R and (-) S enantiomers, respectively
Metabolism: metabolized hepatically by enzymes of the cytochrome P450 enzyme system.
Elimination: excreted in the urine as unchanged drug is less than 0.7% of the dose.
Half-life of thalidomide is 5 to 7 hours.
Dosage and administration
The Oncothal dosage recommendation of following condition as follows
The prescribed dose is 200mg PO qHS in 28-day cycles
Administer 40 mg of dexamethasone on days 1-4,9-12,17-20 of 28 days.
Erythema Nodosum leprosum
The startingprescribed dose is 100-300 mg PO qHS.
If more severe reaction then may start at 400mg. Extend until active symptoms diminish, at least 2 weeks then titrate down by 50 mg increment q 2-4 weeks.
Oncothal 100mg observes following side effects as follows
- Neck rigidity
- Increased bilirubin
- Venous and arterial thromboembolism
- Increased Mortality
- Drowsiness and somnolence
- Peripheral neuropathy
- Dizziness and orthostatic hypotension
- Increased HIV viral load
- Tumor Lysis
Interaction of Oncothal 100mg with opioids, antihistamines, antipsychotics, anti-anxiety agents, other CNS depressants may lead to additive sedative effect.
Concomitant use of Oncothal 100mg with cardiovascular medication will cause an additive bradycardic effect and should be used with caution.
Concomitant use with bortezomib, amiodarone, cisplatin, docetaxel, paclitaxel, vincristine etc will cause peripheral neuropathy and should be used with caution.
Unknown condition when concomitant use of hormonal contraceptives further increases the risk of thromboembolism with Oncothal
Pregnancy - the drug cause risk to fetal
For women of childbearing probably should use contraception 4 weeks before you can start Oncothal. The manufacturer needed you to take a pregnancy test every month before you initiate a new prescription of thalidomide. This is to confirm that you or your significant other is not pregnant. Consult with your doctor when you may safely become pregnant or conceive a child after treatment.
Starting beforeOncothal treatment, make sure to inform doctor about any other medications you are taking (containing prescription, over-the-counter, vitamins, herbal remedies, etc.). Avoid taking aspirin, or products including aspirin untilthe doctor especially permits this.
Do not administerdrugswhich may cause drowsiness without first consulting your health care provider. Also avoid alcohol.
For both men and women use contraceptives, and do not conceive a child (get pregnant) while taking Oncothal. serious, life-threatening birth defects may have reported with even one 50 mg dose. Methods of contraception has two types, such as latex condoms and spermicides, are required.
Avoid breast feed while taking this Oncothal therapy.
Pregnancy category X
Oncothal should not administer to a pregnant woman or a woman who aims to become pregnant.
Oncothal may cause risk to fetal when administer to a pregnant woman.
If a woman becomes pregnant during Oncothal therapy, the drug must be discontinued immediately, and the woman given correct counselling.
There has no data available for the presence of Oncothal in human milk and effects of drug on breastfed infants.
Avoid breastfeeding during treatment with Oncothal 100mg
Store at 200C – 250C
Protect the drug from light
If dose is missed by patient, then take the dose immediately before next dose duration. Next dose time reaches then left off the missed dose and continues regular schedule.Avoid have double dose at same time.Must consult the doctor for further information.
- Trade name Oncothal 100mg
- Substance Thalidomide
- Manufacturer Cadila pharmaceuticals Ltd
- Packaging 10 capsules
- Country of origin India